ALLO

Allogene Therapeutics Stock Price

30.76
-0.58 (-1.85%)
Upgrade to Real-Time
Afterhours (Closed)
30.76
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Allogene Therapeutics Inc ALLO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.58 -1.85% 30.76 20:00:00
Open Price Low Price High Price Close Price Prev Close
30.67 30.43 31.285 30.76 31.34
Bid Price Ask Price Spread News
30.40 33.00 2.60 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,338 458,511 $ 30.78 $ 14,111,964 1,061,300 17.43 - 55.00
Last Trade Time Type Quantity Stock Price Currency
16:23:42 6 $ 30.60 USD

Allogene Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.32B 140.28M 84.05M $ - $ - -1.82 -14.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -23.41k 3.20%

more financials information »

Allogene Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALLO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week31.2433.6430.4331.921,044,626-0.48-1.54%
1 Month27.4633.6424.8528.71857,2613.3012.02%
3 Months35.4136.2524.8529.51961,597-4.65-13.13%
6 Months41.1244.9224.8532.77740,837-10.36-25.19%
1 Year25.6355.0017.4334.05841,7725.1320.02%
3 Years22.0055.0017.4331.22659,7488.7639.82%
5 Years22.0055.0017.4331.22659,7488.7639.82%

Allogene Therapeutics Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.


Your Recent History
NASDAQ
ALLO
Allogene T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.